School of Pharmacy, Faculty of Health and Medical Sciences, Taylor's University, Subang Jaya, Malaysia.
Department of Pharmaceutical Technology, School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
Front Public Health. 2020 Dec 9;8:606129. doi: 10.3389/fpubh.2020.606129. eCollection 2020.
Sudden outbreak of a new pathogen in numbers of pneumonic patients in Wuhan province during December 2019 has threatened the world population within a short period of its occurrence. This respiratory tract-isolated pathogen was initially named as novel coronavirus 2019 (nCoV-2019), but later termed as SARS-CoV-2. The rapid spreading of this infectious disease received the label of pandemic by the World Health Organization within 4 months of its occurrence, which still seeks continuous attention of the researchers to prevent the spread and for cure of the infected patients. The propagation of the disease has been recorded in 215 countries, with more than 25.5 million cases and a death toll of more than 0.85 million. Several measures are taken to control the disease transmission, and researchers are actively engaged in finding suitable therapeutics to effectively control the disease to minimize the mortality and morbidity rates. Several existing potential candidates were explored in the prevention and treatment of worsening condition of COVID-19 patients; however, none of the formulation has been approved for the treatment but used under medical supervision. In this article, a focus has been made to highlight on current epidemiology on the COVID-19 infection, clinical features, diagnosis, and transmission, with special emphasis on treatment measures of the disease at different stages of clinical research and the global economic influence due to this pandemic situation. Progress in the development on vaccine against COVID-19 has also been explored as important measures to immunize people. Moreover, this article is expected to provide information to the researchers, who are constantly combating in the management against this outbreak.
2019 年 12 月,湖北省爆发了大量肺炎患者的新型病原体,在短时间内对世界人口构成威胁。这种呼吸道分离的病原体最初被命名为新型冠状病毒 2019(nCoV-2019),但后来被称为 SARS-CoV-2。这种传染病的迅速传播在其发生后 4 个月内被世界卫生组织贴上了大流行的标签,这仍然需要研究人员继续关注,以防止疾病的传播和感染患者的治疗。该疾病的传播已在 215 个国家记录,超过 2550 万例病例,超过 85 万人死亡。已经采取了几种措施来控制疾病的传播,研究人员正在积极寻找合适的治疗方法来有效控制疾病,以尽量降低死亡率和发病率。已经探索了几种现有潜在的候选药物来预防和治疗 COVID-19 患者病情恶化;然而,没有一种制剂被批准用于治疗,但在医疗监督下使用。本文重点介绍 COVID-19 感染的当前流行病学、临床特征、诊断和传播,并特别强调了不同阶段临床研究的疾病治疗措施以及这种大流行情况对全球经济的影响。还探讨了 COVID-19 疫苗的开发进展,因为这是免疫接种的重要措施。此外,本文预计将为研究人员提供信息,他们一直在努力管理这一疫情爆发。